Goldman on Vertex: We Await Orkambi Pricing Details, Expect To Be On Par WIth Kalydeco ($312K/Yr) Given Strong Secondary Endpoint And Historical Analysis Of Orphan Drug Pricing
July 02, 2015 at 12:58 PM EDT
Goldman expects investor focus to shift over to the drug's trajectory and company's earnings power.